About us Contacts Drug interactions: 390 212
Drug search by name

Defitelio and Fedratinib Hydrochloride

Determining the interaction of Defitelio and Fedratinib Hydrochloride and the possibility of their joint administration.

Check result:
Defitelio <> Fedratinib Hydrochloride
Relevance: 09.10.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.MONITOR CLOSELY: Coadministration of defibrotide with antiplatelet agents or other agents that affect coagulation may increase the risk of bleeding. In vitro, defibrotide increased the activity of fibrinolytic enzymes. In a mouse model of thromboembolism, recombinant tissue plasminogen activator (t-PA) potentiated the antithrombotic effect of defibrotide when given intravenously. MANAGEMENT: Concomitant use of medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with defibrotide. Close clinical and laboratory observation for bleeding complications is recommended during therapy. If bleeding develops, defibrotide should be discontinued and treatment/supportive care provided until the bleeding stops. References "Product Information. Defitelio (defibrotide)." Jazz Pharmaceuticals, Palo Alto, CA. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Professional:

MONITOR CLOSELY: Coadministration of defibrotide with antiplatelet agents or other agents that affect coagulation may increase the risk of bleeding. In vitro, defibrotide increased the activity of fibrinolytic enzymes. In a mouse model of thromboembolism, recombinant tissue plasminogen activator (t-PA) potentiated the antithrombotic effect of defibrotide when given intravenously.

MANAGEMENT: Concomitant use of medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with defibrotide. Close clinical and laboratory observation for bleeding complications is recommended during therapy. If bleeding develops, defibrotide should be discontinued and treatment/supportive care provided until the bleeding stops.

References
  • "Product Information. Defitelio (defibrotide)." Jazz Pharmaceuticals, Palo Alto, CA.
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Defitelio

Generic Name: defibrotide

Brand name: Defitelio

Synonyms: n.a.

Fedratinib Hydrochloride

Generic Name: fedratinib

Brand name: Inrebic

Synonyms: Fedratinib

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction